<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01044758</url>
  </required_header>
  <id_info>
    <org_study_id>NA_00030573</org_study_id>
    <secondary_id>RC2AG036419</secondary_id>
    <nct_id>NCT01044758</nct_id>
  </id_info>
  <brief_title>Levetiracetam and Memory Function in Amnestic Mild Cognitive Impairment (MCI)</brief_title>
  <official_title>Bridging Cognitive Aging in Rodents to Man Using fMRI in Amnestic MCI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research is being done to find out if daily use of the drug levetiracetam can improve
      memory function in individuals with memory problems like those associated with Mild Cognitive
      Impairment (MCI) and Alzheimer's disease (AD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Increasing research is focused on conditions that precede the clinical diagnosis of
      Alzheimer's disease (AD) in order to detect patients at risk for early intervention. One such
      condition is mild cognitive impairment (MCI). Functional magnetic resonance imaging (fMRI)
      studies in this group of patients have reported increased activation in the Medial Temporal
      Lobe (MTL) during performance of memory tasks. The functional significance of increased
      activation is unclear. One possibility is that greater activity reflects the increased effort
      needed in order to maintain performance, and as such would be a compensatory response. An
      alternative possibility is that increased activation reflects aberrant physiology related to
      the disease process itself and as such would be a sign of greater underlying disease severity
      and would interfere with brain function.

      Data in animal models suggest the possibility that low dose levetiracetam (well-tolerated
      anti-convulsant) treatment may reduce the observed hyperactivity and improve memory
      performance among individuals with MCI. The investigators are therefore conducting a
      within-subjects trial of 8 weeks duration, involving 144 subjects and low dose treatment with
      levetiracetam. During the course of the study, each subject may receive both drug and placebo
      for two weeks, with the order of administering those treatments counterbalanced. Cognitive
      testing and fMRI imaging will be obtained after 2-weeks on drug/placebo. The overall goal of
      the study is to determine if treatment of MCI subjects with low dose levetiracetam reduces
      hyperactivity within the MTL and improves memory performance.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Brain Activity in the Dentate Gyrus / CA3 Subregion of the Hippocampus Measured With Blood Oxygenation Level Dependent (BOLD) Functional MRI</measure>
    <time_frame>2 weeks</time_frame>
    <description>Measurement of average brain activity in the dentate gyrus / CA3 subregion of the hippocampus measured with BOLD functional MRI in patients with mild cognitive impairment on placebo and on drug compared to average brain activity in this brain area in control subjects.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Behavioral Performance as Assessed in the Functional Magnetic Resonance Imaging (fMRI) Memory Task</measure>
    <time_frame>2 weeks</time_frame>
    <description>Mnemonic similarity task which assesses long term memory function. Scale ranges from 0-100 with higher scores indicating better memory performance.</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">96</enrollment>
  <condition>Mild Cognitive Impairment (MCI)</condition>
  <arm_group>
    <arm_group_label>aMCI_62.5mg drug first, then placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Amnestic MCI:
62.5mg levetiracetam twice daily (two weeks), washout (4 weeks), and placebo capsule twice daily (two weeks)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>aMCI_Placebo first, then 62.5mg drug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Amnestic MCI:
Placebo capsule twice daily (two weeks), washout (4 weeks), and 62.5mg levetiracetam twice daily (two weeks)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>aMCI_125mg drug first, then placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Amnestic MCI:
125mg levetiracetam twice daily (two weeks), washout (4 weeks), and placebo capsule twice daily (two weeks)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>aMCI_Placebo first, then 125mg drug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Amnestic MCI:
Placebo capsule twice daily (two weeks), washout (4 weeks), and 125mg levetiracetam twice daily (two weeks)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>aMCI_250mg drug first, then placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Amnestic MCI: 250mg levetiracetam twice daily (two weeks), washout (4 weeks), and placebo capsule twice daily (two weeks)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>aMCI_Placebo first, then 250mg drug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Amnestic MCI:
Placebo capsule twice daily (two weeks), washout (4 weeks), and 250mg levetiracetam twice daily (two weeks)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control_Placebo first, then placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Healthy control:
placebo capsule twice daily (two weeks), washout (4 weeks), and placebo capsule twice daily (two weeks)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levetiracetam 62.5mg</intervention_name>
    <description>62.5mg twice daily (2 weeks)</description>
    <arm_group_label>aMCI_62.5mg drug first, then placebo</arm_group_label>
    <arm_group_label>aMCI_Placebo first, then 62.5mg drug</arm_group_label>
    <other_name>Keppra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levetiracetam 125mg</intervention_name>
    <description>125mg twice daily (2 weeks)</description>
    <arm_group_label>aMCI_125mg drug first, then placebo</arm_group_label>
    <arm_group_label>aMCI_Placebo first, then 125mg drug</arm_group_label>
    <other_name>Keppra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levetiracetam 250mg</intervention_name>
    <description>250mg twice daily (2 weeks)</description>
    <arm_group_label>aMCI_250mg drug first, then placebo</arm_group_label>
    <arm_group_label>aMCI_Placebo first, then 250mg drug</arm_group_label>
    <other_name>Keppra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo capsule twice daily (2 weeks)</description>
    <arm_group_label>aMCI_62.5mg drug first, then placebo</arm_group_label>
    <arm_group_label>aMCI_Placebo first, then 62.5mg drug</arm_group_label>
    <arm_group_label>aMCI_125mg drug first, then placebo</arm_group_label>
    <arm_group_label>aMCI_Placebo first, then 125mg drug</arm_group_label>
    <arm_group_label>aMCI_250mg drug first, then placebo</arm_group_label>
    <arm_group_label>aMCI_Placebo first, then 250mg drug</arm_group_label>
    <arm_group_label>Control_Placebo first, then placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All: English as a first language; right handed; able to complete written informed
             consent.

          -  MCI subjects: In addition to above, must meet criteria for amnestic Mild Cognitive
             Impairment (MCI). This includes a memory complaint corroborated by an informant;
             impaired memory function for age and educational level; preserved general cognitive
             function; intact abilities of daily living; no clinical dementia.

          -  Age matched Controls: Must have memory and cognitive status that is normal for their
             age.

        Exclusion Criteria:

          -  Familial Alzheimer's Disease (AD) due to known genetic mutations

          -  AD with Parkinsonian features; major psychiatric or behavioral disorders (e.g.
             depression, agitation, psychosis, manic-depressive disorder)

          -  Primary or metastatic intracranial neoplasm

          -  History of severe head trauma

          -  Intra-cerebral hemorrhage

          -  Seizure disorder

          -  Hemispheric stroke

          -  Presence of a progressive central nervous system disease

          -  Presence of lacunar infarcts

          -  Medical contraindications to MRI including cardiac pacemaker, presence of intraocular
             or intracranial metallic objects

          -  Any known allergy to levetiracetam or behavioral problems that are a contraindication
             to taking Levetiracetam (e.g. agitation)

          -  Prescribed use of anti-seizure medications.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gregory L Krauss, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins University School of Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Busche MA, Eichhoff G, Adelsberger H, Abramowski D, Wiederhold KH, Haass C, Staufenbiel M, Konnerth A, Garaschuk O. Clusters of hyperactive neurons near amyloid plaques in a mouse model of Alzheimer's disease. Science. 2008 Sep 19;321(5896):1686-9. doi: 10.1126/science.1162844.</citation>
    <PMID>18802001</PMID>
  </reference>
  <reference>
    <citation>Bakker A, Kirwan CB, Miller M, Stark CE. Pattern separation in the human hippocampal CA3 and dentate gyrus. Science. 2008 Mar 21;319(5870):1640-2. doi: 10.1126/science.1152882.</citation>
    <PMID>18356518</PMID>
  </reference>
  <reference>
    <citation>Palop JJ, Chin J, Roberson ED, Wang J, Thwin MT, Bien-Ly N, Yoo J, Ho KO, Yu GQ, Kreitzer A, Finkbeiner S, Noebels JL, Mucke L. Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron. 2007 Sep 6;55(5):697-711.</citation>
    <PMID>17785178</PMID>
  </reference>
  <reference>
    <citation>Sperling R, Greve D, Dale A, Killiany R, Holmes J, Rosas HD, Cocchiarella A, Firth P, Rosen B, Lake S, Lange N, Routledge C, Albert M. Functional MRI detection of pharmacologically induced memory impairment. Proc Natl Acad Sci U S A. 2002 Jan 8;99(1):455-60. Epub 2001 Dec 26.</citation>
    <PMID>11756667</PMID>
  </reference>
  <reference>
    <citation>Wilson IA, Ikonen S, Gallagher M, Eichenbaum H, Tanila H. Age-associated alterations of hippocampal place cells are subregion specific. J Neurosci. 2005 Jul 20;25(29):6877-86.</citation>
    <PMID>16033897</PMID>
  </reference>
  <reference>
    <citation>Wilson IA, Gallagher M, Eichenbaum H, Tanila H. Neurocognitive aging: prior memories hinder new hippocampal encoding. Trends Neurosci. 2006 Dec;29(12):662-70. Epub 2006 Oct 13. Review.</citation>
    <PMID>17046075</PMID>
  </reference>
  <reference>
    <citation>Koh MT, Haberman RP, Foti S, McCown TJ, Gallagher M. Treatment strategies targeting excess hippocampal activity benefit aged rats with cognitive impairment. Neuropsychopharmacology. 2010 Mar;35(4):1016-25. doi: 10.1038/npp.2009.207. Epub 2009 Dec 23.</citation>
    <PMID>20032967</PMID>
  </reference>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 7, 2010</study_first_submitted>
  <study_first_submitted_qc>January 7, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 8, 2010</study_first_posted>
  <results_first_submitted>September 8, 2014</results_first_submitted>
  <results_first_submitted_qc>July 19, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">August 21, 2017</results_first_posted>
  <last_update_submitted>July 19, 2017</last_update_submitted>
  <last_update_submitted_qc>July 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mild Cognitive Impairment</keyword>
  <keyword>Amnestic Mild Cognitive Impairment</keyword>
  <keyword>Functional Magnetic Resonance Imaging</keyword>
  <keyword>Levetiracetam</keyword>
  <keyword>Keppra</keyword>
  <keyword>Medial Temporal Lobe</keyword>
  <keyword>Memory Impairment</keyword>
  <keyword>Alzheimer's Disease</keyword>
  <keyword>AD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etiracetam</mesh_term>
    <mesh_term>Piracetam</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Data for the 125mg BID treatment cohort was collected first. Analysis showed no effects of treatment order. As a result, data was collapsed and analyzed irrespective of order across all doses. All subsequent data analyses are thus provided collapsed across treatment orders in all reporting on this study, including the results reported here.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>aMCI_62.5mg Drug First, Then Placebo</title>
          <description>Amnestic MCI:
62.5mg levetiracetam twice daily (two weeks), washout (4 weeks), and placebo capsule twice daily (two weeks)</description>
        </group>
        <group group_id="P2">
          <title>aMCI_Placebo First, Then 62.5mg Drug</title>
          <description>Amnestic MCI:
Placebo capsule twice daily (two weeks), washout (4 weeks), and 62.5mg levetiracetam twice daily (two weeks)</description>
        </group>
        <group group_id="P3">
          <title>aMCI_125mg Drug First, Then Placebo</title>
          <description>Amnestic MCI:
125mg levetiracetam twice daily (two weeks), washout (4 weeks), and placebo capsule twice daily (two weeks)</description>
        </group>
        <group group_id="P4">
          <title>aMCI_Placebo First, Then 125mg Drug</title>
          <description>Amnestic MCI:
Placebo capsule twice daily (two weeks), washout (4 weeks), and 125mg levetiracetam twice daily (two weeks)</description>
        </group>
        <group group_id="P5">
          <title>aMCI_250mg Drug First, Then Placebo</title>
          <description>Amnestic MCI:
250mg levetiracetam twice daily (two weeks), washout (4 weeks), and placebo capsule twice daily (two weeks)</description>
        </group>
        <group group_id="P6">
          <title>aMCI_Placebo First, Then 250mg Drug</title>
          <description>Amnestic MCI:
Placebo capsule twice daily (two weeks), washout (4 weeks), and 250mg levetiracetam twice daily (two weeks)</description>
        </group>
        <group group_id="P7">
          <title>Control_Placebo First, Then Placebo</title>
          <description>Healthy control:
placebo capsule twice daily (two weeks), washout (4 weeks), and placebo capsule twice daily (two weeks)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="11"/>
                <participants group_id="P6" count="11"/>
                <participants group_id="P7" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="9"/>
                <participants group_id="P6" count="8"/>
                <participants group_id="P7" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>aMCI_62.5mg Drug First, Then Placebo</title>
          <description>Amnestic MCI:
62.5mg levetiracetam twice daily (two weeks), washout (4 weeks), and placebo capsule twice daily (two weeks)</description>
        </group>
        <group group_id="B2">
          <title>aMCI_Placebo First, Then 62.5mg Drug</title>
          <description>Amnestic MCI:
Placebo capsule twice daily (two weeks), washout (4 weeks), and 62.5mg levetiracetam twice daily (two weeks)</description>
        </group>
        <group group_id="B3">
          <title>aMCI_125mg Drug First, Then Placebo</title>
          <description>Amnestic MCI:
125mg levetiracetam twice daily (two weeks), washout (4 weeks), and placebo capsule twice daily (two weeks)</description>
        </group>
        <group group_id="B4">
          <title>aMCI_Placebo First, Then 125mg Drug</title>
          <description>Amnestic MCI:
Placebo capsule twice daily (two weeks), washout (4 weeks), and 125mg levetiracetam twice daily (two weeks)</description>
        </group>
        <group group_id="B5">
          <title>aMCI_250mg Drug First, Then Placebo</title>
          <description>Amnestic MCI:
250mg levetiracetam twice daily (two weeks), washout (4 weeks), and placebo capsule twice daily (two weeks)</description>
        </group>
        <group group_id="B6">
          <title>aMCI_Placebo First, Then 250mg Drug</title>
          <description>Amnestic MCI:
Placebo capsule twice daily (two weeks), washout (4 weeks), and 250mg levetiracetam twice daily (two weeks)</description>
        </group>
        <group group_id="B7">
          <title>Control_Placebo First, Then Placebo</title>
          <description>Healthy control
placebo capsule twice daily (two weeks), washout (4 weeks), and placebo capsule twice daily (two weeks)</description>
        </group>
        <group group_id="B8">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="7"/>
            <count group_id="B4" value="10"/>
            <count group_id="B5" value="9"/>
            <count group_id="B6" value="8"/>
            <count group_id="B7" value="17"/>
            <count group_id="B8" value="71"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="7"/>
                    <measurement group_id="B7" value="16"/>
                    <measurement group_id="B8" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="8"/>
                    <measurement group_id="B8" value="41"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="9"/>
                    <measurement group_id="B8" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="9"/>
                    <measurement group_id="B6" value="8"/>
                    <measurement group_id="B7" value="17"/>
                    <measurement group_id="B8" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Brain Activity in the Dentate Gyrus / CA3 Subregion of the Hippocampus Measured With Blood Oxygenation Level Dependent (BOLD) Functional MRI</title>
        <description>Measurement of average brain activity in the dentate gyrus / CA3 subregion of the hippocampus measured with BOLD functional MRI in patients with mild cognitive impairment on placebo and on drug compared to average brain activity in this brain area in control subjects.</description>
        <time_frame>2 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>aMCI_62.5</title>
            <description>62.5 mg levetiracetam twice daily for two weeks</description>
          </group>
          <group group_id="O2">
            <title>aMCI_62.5 Placebo</title>
            <description>62.5mg levetiracetam placebo comparator</description>
          </group>
          <group group_id="O3">
            <title>aMCI_125</title>
            <description>125 mg Levetiracetam twice daily for two weeks.</description>
          </group>
          <group group_id="O4">
            <title>aMCI_125 Placebo</title>
            <description>125mg levetiracetam placebo comparator</description>
          </group>
          <group group_id="O5">
            <title>aMCI_250</title>
            <description>250mg levetiracetam twice daily for two weeks</description>
          </group>
          <group group_id="O6">
            <title>aMCI_250 Placebo</title>
            <description>250mg levetiracetam placebo comparator</description>
          </group>
          <group group_id="O7">
            <title>Age Matched Control</title>
            <description>Placebo capsule twice daily for two weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Brain Activity in the Dentate Gyrus / CA3 Subregion of the Hippocampus Measured With Blood Oxygenation Level Dependent (BOLD) Functional MRI</title>
          <description>Measurement of average brain activity in the dentate gyrus / CA3 subregion of the hippocampus measured with BOLD functional MRI in patients with mild cognitive impairment on placebo and on drug compared to average brain activity in this brain area in control subjects.</description>
          <units>mean beta coefficient</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="17"/>
                <count group_id="O5" value="17"/>
                <count group_id="O6" value="17"/>
                <count group_id="O7" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1203" spread="0.3475"/>
                    <measurement group_id="O2" value="0.4353" spread="0.2215"/>
                    <measurement group_id="O3" value="-0.2238" spread="0.1747"/>
                    <measurement group_id="O4" value="0.8814" spread="0.3798"/>
                    <measurement group_id="O5" value="0.3928" spread="0.2366"/>
                    <measurement group_id="O6" value="0.4825" spread="0.1954"/>
                    <measurement group_id="O7" value="-.02507" spread=".2238"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Behavioral Performance as Assessed in the Functional Magnetic Resonance Imaging (fMRI) Memory Task</title>
        <description>Mnemonic similarity task which assesses long term memory function. Scale ranges from 0-100 with higher scores indicating better memory performance.</description>
        <time_frame>2 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>aMCI_62.5</title>
            <description>62.5mg levetiracetam twice daily for two weeks</description>
          </group>
          <group group_id="O2">
            <title>aMCI_62.5 Placebo</title>
            <description>62.6mg levetiracetam placebo comparator</description>
          </group>
          <group group_id="O3">
            <title>aMCI_125</title>
            <description>125mg levetiracetam twice daily for two weeks</description>
          </group>
          <group group_id="O4">
            <title>aMCI_125 Placebo</title>
            <description>125mg levetiracetam placebo comparator</description>
          </group>
          <group group_id="O5">
            <title>aMCI_250</title>
            <description>250mg levetiracetam twice daily for two weeks</description>
          </group>
          <group group_id="O6">
            <title>aMCI_250 Placebo</title>
            <description>250mg levetiracetam placebo comparator</description>
          </group>
          <group group_id="O7">
            <title>Age Matched Control</title>
            <description>Placebo capsule twice daily for two weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Behavioral Performance as Assessed in the Functional Magnetic Resonance Imaging (fMRI) Memory Task</title>
          <description>Mnemonic similarity task which assesses long term memory function. Scale ranges from 0-100 with higher scores indicating better memory performance.</description>
          <units>percent correct recalled</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="17"/>
                <count group_id="O5" value="17"/>
                <count group_id="O6" value="17"/>
                <count group_id="O7" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38" spread="4"/>
                    <measurement group_id="O2" value="33" spread="5"/>
                    <measurement group_id="O3" value="33" spread="5"/>
                    <measurement group_id="O4" value="28" spread="4"/>
                    <measurement group_id="O5" value="34" spread="4"/>
                    <measurement group_id="O6" value="31" spread="3"/>
                    <measurement group_id="O7" value="44" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>aMCI_62.5</title>
          <description>62.5 mg levetiracetam twice daily for two weeks</description>
        </group>
        <group group_id="E2">
          <title>aMCI_62.5 Placebo</title>
          <description>62.5 mg placebo comparator (placebo capsule twice daily for two weeks)</description>
        </group>
        <group group_id="E3">
          <title>aMCI_125</title>
          <description>125 mg levetiracetam twice daily for two weeks</description>
        </group>
        <group group_id="E4">
          <title>aMCI_125 Placebo</title>
          <description>125 mg placebo comparator (placebo capsule twice daily for two weeks)</description>
        </group>
        <group group_id="E5">
          <title>aMCI_250</title>
          <description>250 mg levetiracetam twice daily for two weeks</description>
        </group>
        <group group_id="E6">
          <title>aMCI_250 Placebo</title>
          <description>250 mg placebo comparator (placebo capsule twice daily for two weeks)</description>
        </group>
        <group group_id="E7">
          <title>Age Matched Control</title>
          <description>placebo capsule twice daily for two weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>somnolence</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="6" subjects_affected="5" subjects_at_risk="22"/>
                <counts group_id="E6" events="6" subjects_affected="4" subjects_at_risk="22"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gregory Krauss, M.D.</name_or_title>
      <organization>Johns Hopkins University School of Medicine</organization>
      <phone>(410) 955-2822</phone>
      <email>gkrauss@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

